Member Info for B2HS2L

Hillseeker,

https://genesig.com//assets/files/SNPsig_SARS_CoV_2_N501Y_Version_1_1_Handbook.pdf

This is the handbook for the 'Variants with the N501Y mutation (UK, SA and Brazilian)'.

I hope this provides further info on what the product does.

A reference at the bottom of the Peac*ck article to a 03.02.2021 story on the threat of E484K on this link, and worth a read:

https://theconversation.com/concerning-coronavirus-mutation-now-found-in-uk-variant-heres-what-you-need-to-know-153248

Concerning coronavirus mutation now found in UK variant – here’s what you need to know

"If there’s one coronavirus mutation that keeps scientists awake at night, it’s E484K. The mutation was found in both the South African variant (B1351) and the Brazilian variant (P1), but not in the UK variant (B117). This so-called “escape mutation” raised fears that the approved COVID vaccines may not be as effective against these variants. The E484K mutation has now been found in the UK variant as well – albeit in just 11 cases." (as at 03.02.2021).

"The coronavirus mutates slowly, accumulating around two single-letter mutations per month in its genome. This rate of change is about half that of flu viruses. Early in the pandemic, few scientists were worried that the coronavirus would mutate into something more dangerous. But in November 2020, that swiftly changed when the first “variant of concern” was discovered. The newly discovered variant B117 was associated with the huge spike in cases in south-east England and London."

https://codiagnostics.com/about/videos-multimedia/

Wilson, these are some videos (some pre pandemic) from the CEO of codiagnostics that we bought the licence from.
Very impressive, particularly the fifth one, - interview with founder Dr Satterfield.

...and a rather unusual way for a professional person to sign off - me thinks.

At 16:00 GMT today.

May get further info on testing intentions, and / or further detail on how the $50 Bil will be spent.

https://www.whitehouse.gov/live/

Harv 54 - You wrote on the 10 Feb at 16:46 :

I am a big supporter of Novacyt but you don't want to take the test systems away from laboratories, you want them integrated as the best available test method within them. The problem of non laboratory testing is that it moves towards testing with staff not trained in the quality procedures required for clinical diagnostic testing with disastrous results. Having satallite lab's in strategic places under the supervision of professional lab. staff is what you want in the long term.

++++

It does not sound as though you are a big fan of PROmate, that only requires one pipette operation (as I understand it).

From 16.11.2021 RNS
"Novacyt continues to innovate in its response to the rapidly changing needs of the COVID-19 testing market. In particular, the launch of PROmate™ is expected to further improve the workflow efficiency of our near-patient testing system, enabling reduced operator complexity and faster cycle times for our market leading PCR COVID-19 test. "

From 29.01.2021 RNS:
"Novacyt's PROmate™, a new product to improve the workflow efficiency when used with the Company's q16/q32 instruments successfully completed an in-service validation conducted by Test and Trace's Technology Validation Group (TVG), with the TVG concluding the performance of the PROmate™ aligns with the acceptable standard for point-of-care (rapid testing)."

It seems an innovative done deal for Near Patient Testing, with no equivalent product on offer elsewhere.
Do you agree, & if not then why not please?

The link has an extra bracket it does not need.
try this one:
https://www.life-sciences-usa.com/news/lab21-acquires-new-real-ltd-novacyt-group-cooperative-2001-98705.html

Thanks Wilson, great finds.

The second link mentions 2018 as being in the future, so the predicted market sizes are probably useless now we are mid - pandemic.

We know Novacyt developed a viable Covid-19 test fast. (probably through use of a licence described at this link:
https://www.life-sciences-usa.com/news/lab21-acquires-new-real-ltd-novacyt-group-cooperative-2001-98705.html).
NCYT established / have been enjoying first mover advantage since.

This means that for any future molecular diagnostic requirement, Novacyt will have a significant time to development advantage, although some other companies now use Bioinformatics to try to development tests quickly.
NCYT even beat co-operative diagnostics in the time it took to get an FDA EUA for their Covid-19 test last year!

Deas, - Is this idea too strong:

GM to release a video providing an update on the DHSC ph1 / ph1 extension / phase 2 negotiations or
renegotiations (with associated RNS), thus addressing some PI concern over communications / PR.

Not very likely in my estimation, but not impossible.

He would get more bang for his buck if he released this kind of news with a new product launch.

Deas, -
Wasn't there something from the video production company talking about shooting new video's, and that it wasn't long before they were going to be released. - (Great to be working with such a great company etc)?

If it is a new video, why?:

New product announcement:
· Development of a loop-mediated isothermal amplification (LAMP) test for COVID-19
· Development of an antibody lateral flow test (LFT) for COVID-19

Or Could be plugging PROmate + instruments

Wilson,

There has not been any further mention of 'transplant' for 3 months odd.
Our new target must now be Bioinformatics (I'm certain).

So instead of me expecting an M&A announcement with a company involved with transplants, I now expect one with a company involved in Bioinformatics.

Sorry your post has been removed from last night containing a link to a hilarious scots guy with a great set of sketches.
Particularly liked his Nicola Sturgeon p takes.
Have you got anymore like that?

Harv 54 - You wrote on the 10 Feb at 16:46 :

I am a big supporter of Novacyt but you don't want to take the test systems away from laboratories, you want them integrated as the best available test method within them. The problem of non laboratory testing is that it moves towards testing with staff not trained in the quality procedures required for clinical diagnostic testing with disastrous results. Having satallite lab's in strategic places under the supervision of professional lab. staff is what you want in the long term.

++++

It does not sound as though you are a big fan of PROmate, that only requires one pipette operation (as I understand it).

From 16.11.2021 RNS
"Novacyt continues to innovate in its response to the rapidly changing needs of the COVID-19 testing market. In particular, the launch of PROmate™ is expected to further improve the workflow efficiency of our near-patient testing system, enabling reduced operator complexity and faster cycle times for our market leading PCR COVID-19 test. "

From 29.01.2021 RNS:
"Novacyt's PROmate™, a new product to improve the workflow efficiency when used with the Company's q16/q32 instruments successfully completed an in-service validation conducted by Test and Trace's Technology Validation Group (TVG), with the TVG concluding the performance of the PROmate™ aligns with the acceptable standard for point-of-care (rapid testing)."

It seems an innovative done deal for Near Patient Testing, with no equivalent product on offer elsewhere.
Do you not agree, & if not then why not please?

Grateful for your help Wilson, I'm getting side-tracked myself, and intend to finish off tonight.

Ref your 14:46 post, It finds evidence of use of the Primerdesign assay, but not how many kits were required.

Further to the 12:17 post -

Irish Coronavirus Sequencing Consortium

https://www.teagasc.ie/food/research-and-innovation/research-areas/food-bioscience/irish-coronavirus-sequencing-consortium/

My next job is to pick out the establishments mentioned in this article and identify whether they are connected in any way with Novacyt, or preferably how much Novacyt kit they bought.
Any help gratefuly accepted!

Further to the 10:31 post -

IMO the speed of development of SNPsig and VARIplex, are down to two factors:

1 From a 26.01.2021 post titled 'The nature of [NCYT] competitive advantage':

The links below go some way to explaining our competitive edge that was evident when the virus was first identified.
Within three months NCYT had a test good enough to be championed by none other than World Health Organisation, and has since proven to identify Covid-19 so accurately.
Read these two links in the order presented for an explanation

https://whosonthemove.com/cooperative-diagnostics-an-sc-launch-company-uses-advanced-mathematics-to-produce-diagnostics-in-less-than-16-days-163855/

https://www.life-sciences-usa.com/news/lab21-acquires-new-real-ltd-novacyt-group-cooperative-2001-98705.html

2 The use of Chartwell Consulting to plan and facilitate very fast ramp up of production of new products, as they must have done prior to and during the purchase of IT-IS International.

From 'Half year 2020 results' RNS 17.09.2020
" . New strategy implemented to continue growth trajectory and consolidate performance through broadening focus on respiratory and transplant clinical diagnostics".

Note the word 'transplant'.

From 'R&D Update' RNS - 16.11.2020:
"In the medium-term, Novacyt expects to leverage its reputation, market intelligence and relationships developed during the COVID-19 response to commercialise new products, as well as expand its presence in respiratory and transplant clinical diagnostics, to continue to meet significant unmet market needs."

This was the last time the word 'transplant' was used discussing clinical diagnostic new products.

From 'Executive Management and Proposed Board Changes' 05.01.2020 RNS:
"His [Anthony Dyer's] new, important role reflects the Company's growth strategy, which includes selective potential M&A to supplement organic growth initiatives."

From RNS - Full Year 2020 Trading Update - 29.01.2021:
"Anthony Dyer has taken on a new role as Chief Corporate Development Officer to focus on executing against the Company's ambitious organic growth and innovation strategy, as well as its M&A strategy to supplement growth initiatives."

Also from the same document this, - the most clearly expressed statement of growth strategy yet:

"With the strengthened cash position of the Company, the business is able to continue to invest in innovation, organic expansion and external business development, in line with its growth strategy, to leverage its strong momentum as a leading European molecular diagnostic player in infectious diseases. Organically, Novacyt will continue to invest in its commercial infrastructure to deliver new products, as the Company continues to redefine its R&D pipeline and establish a direct sales force in key markets in the US and across Europe. The Company also continues to evaluate M&A opportunities and will consider additional bolt-on acquisitions to add strategic assets and functionality to the expanding Group."

Nothing here about transplants.

++++
My take is that 'transplants' may still be on the agenda, but the new priority one has become bioinformatics surveillance, spawning the innovative SNPsig product announcement on 02.02.2021 and noting the recent, 'the first three SNPsig® assays are also being deployed to an international consortium of leading academic and public health laboratories in the UK, Europe, US and Latin America7, assembled by Novacyt to support a global variant diagnostic surveillance study.'
Thus establishing first mover advantages again.

Bioinformatics surveillance is a much longer lasting area of research operations for Novacyt, as the market seems to believe there is a relatively finite length of time for Covid-19 testing assay's.
When the market understands this, we will see sp improve as future forward looking statements expand on years of future RNA tracking.

Thank goodness for our Chartwell Consulting r

Great find Quickdraw:

https://www.bioworld.com/articles/503479-covid-19-test-makers-are-adapting-for-variants

virtual handclap emoji.

+++

To all:

https://www.linkedin.com/company/novacyt.co.uk/ (bottom of page)

If anyone has LinkedIn premium - a quick question, who is Novacyt's (female) recent senior manager hire?

Ventura1, -

My point is that I was patient, my investment halved in value but then blossomed.

Others entered at a high recently, and now they're down.

Patience will be rewarded, with these fundamentals.

Things are going to get a lot better very soon when we find out how SNPsig is going to be utilised.

FWIW I spent 5 months spiked after buying shares in April 2020 at £4.75.

Fundamentals are better now than they were then.

The CEO has made a large investment.

Yet all I'm hearing from some is belly-aching.

All that is required is patience here IMO.

Correct Shaun, - saw the prior information notice, and assumed it was all LFT types, as none specified.
Apologies for being too quick off the mark.